Related Experiment Video

Updated: May 26, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Targeted therapy in prostate cancer

Niall M Corcoran1, Martin E Gleave

  • 1Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia. niallmcorcoran@gmail.com

Histopathology
|January 4, 2012
PubMed

Insights

Recent advances in advanced prostate cancer therapy include novel targeted agents, validating pathway analysis and drug design. This review covers key pathways and clinical activity of new targeted therapies for the lethal prostate cancer phenotype.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Advanced prostate cancer treatment has undergone significant evolution in the past decade.
  • Molecular understanding of tumor invasion, metastasis, and resistance has rapidly advanced.
  • This has led to the identification of numerous novel therapeutic targets.

Purpose of the Study:

  • To review key molecular pathways driving the lethal prostate cancer phenotype.
  • To summarize the clinical activity of newly approved and investigational targeted therapies for advanced prostate cancer.

Main Methods:

  • Literature review of recent advancements in prostate cancer therapeutics.
  • Analysis of molecular pathways implicated in prostate cancer progression.
  • Evaluation of clinical trial data for targeted agents.

Main Results:

  • The last 7 years have seen more therapeutic changes than the previous 70.
  • Targeted agents, validated through pathway analysis and drug design, are improving overall survival.
  • A wide range of targeted agents are currently in clinical development.

Conclusions:

  • Targeted therapies represent a promising frontier in advanced prostate cancer treatment.
  • Continued research into molecular circuitry is crucial for developing effective therapies.
  • New agents are showing clinical activity and improving outcomes for patients with advanced prostate cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...